Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice
Food & Function · 2023
DOI: 10.1039/d2fo03701g ↗Kurz gefasst
Fachartikel in der Zeitschrift Food & Function, 2023. Verfasst von Jiayuan Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Ocean University of China, Qingdao, 266000, China. yihx@ouc.edu.cn. Hauptthemen laut MEDLINE: Limosilactobacillus fermentum, Gastrointestinal Microbiome, Hyperuricemia, Probiotics. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
L. fermentum F40-4 could inhibit UA synthetase activity in the liver to decrease UA production, promote expression level of UA excretion transporter NPT1 in the kidney and reshape microbiota in the gut to increase UA excretion, thereby alleviate HUA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- College of Food Science and Engineering, Ocean University of China, Qingdao, 266000, China. yihx@ouc.edu.cn.
- Yangzhou University Healthy source Dairy Co., LTD., Yangzhou, 225002, China. 770362717@qq.com.
Zitieren
APA
Cao, J., Wang, T., Liu, Y., Zhou, W., Hao, H., Liu, Q., Yin, B., & Yi, H. (2023). Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice. Food & Function. https://doi.org/10.1039/d2fo03701g
Vancouver
Cao J, Wang T, Liu Y, Zhou W, Hao H, Liu Q, et al. Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice. Food & Function. 2023. doi:10.1039/d2fo03701g
BibTeX
@article{Cao2023,
author = {Cao, Jiayuan and Wang, Ting and Liu, Yisuo and Zhou, Wei and Hao, Haining and Liu, Qiqi and Yin, Boxing and Yi, Huaxi},
title = {Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice},
journal = {Food & Function},
year = {2023},
doi = {10.1039/d2fo03701g}
}
EUVIMED